Year: 2024

Company Seeks To Reorganize Its Finances While Continuing to Operate Its Business BETHESDA, Md., Dec. 23, 2024 (GLOBE NEWSWIRE) — iLearningEngines, Inc. (NASDAQ: AILE) (“iLearningEngines,” “ILE” or the “Company”), a leader in AI-powered learning and work automation, today announced that on December 20, 2024 the Company voluntarily initiated Chapter 11 proceedings in the United States Bankruptcy Court for the District of Delaware (the “Court”). The Company will seek Court approval to continue operating on a business as usual basis during the proceedings and intends to continue to provide support to its installed customer base that relies on its Applied AI platform to run their businesses. “We appreciate the continued support of our customers, partners and employees, and our hope is that this process will put us in a better position...

Multi-year Contract Builds on Success in Genius™ and Atari Benchmarks for Next-Gen AI VANCOUVER, British Columbia, Dec. 23, 2024 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) (“VERSES” or the “Company”), a cognitive computing company specializing in next-generation intelligent systems, announces that the Company has extended its exclusive contract with Professor Karl Friston, acclaimed neuroscientist, to continue his role as Chief Scientist. The extension includes additional performance-based incentives that recognize recent breakthroughs in research and development and contributions to its flagship product Genius™ and further expected technological advancements. “Our work with Professor Friston has exceeded our expectations,” said Gabriel René, founder and CEO of VERSES. “His revolutionary...

Yara has today transferred to Fernanda Lopes Larsen, Yara EVP, Africa & Asia, member of Yara’s Group Executive Board, a total of 2,129 Yara shares (ticker: YAR, ISIN: NO0010208051) at an average price of NOK 305.30 per share. Following this purchase, Fernanda Lopes Larsen owns a total of 13,915 shares in Yara international ASA. In order to support alignment between members of the Group Executive Board and shareholder interests, it is expected that members of the Group Executive Board participating in Yara’s Share Based Remuneration program (SBR), in addition to the shares received as part of the SBR, invest in Yara shares an amount equalling the lowest amount received as net, after tax short-term incentive plan payout for the preceding year or the net amount received as SBR for the relevant year, and do so yearly as a...

Main Assembly Finalized–Further Progressing Strategic Plan MONROE TOWNSHIP, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (NYSE American: OPTT) (“OPT” or the “Company”), a leader in innovative and cost-effective low-carbon marine power, data, and service solutions, today announced it has finalized the main assembly of the previously announced PowerBuoy® for Naval Postgraduate School. The full system, which includes installing AT&T® 5G technology and integrating advanced subsea sensors into a PowerBuoy® equipped with OPT’s latest Merrows™ suite for AI capable seamless integration of Maritime Domain Awareness (MDA) across platforms, is now being readied for shipment ready for deployment in early 2025 alongside the Technology Showcase NPS is hosting in January. Once deployed, the PowerBuoy®...

Company Expected Notice for Continued Deficiency and Delist Letter from the Nasdaq Stock Market Company Intends to Request Hearing to Appeal in a Timely Manner MIRAMAR, Fla., Dec. 23, 2024 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported on December 17, 2024, the Company received written notice from the Listing Qualifications Staff (“Staff”) that it had failed to re-gain compliance for continued listing requirements of the Nasdaq Global Markets. As previously disclosed, on June 20, 2024, the Company received written notice from the Staff, which notified the Company that, for the 30...

HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) — Intuitive Machines, Inc. (Nasdaq: LUNR, LUNRW) (“Intuitive Machines” or the “Company”), a space exploration, infrastructure, and services company, has secured additional contracts from NASA’s Near Space Network (“NSN”) for Direct-to-Earth (“DTE”) services. These contracts further position Intuitive Machines as a vital partner in supporting NASA’s missions to the Moon, and beyond. DTE communication and navigation services are critical for enabling missions to exit Earth’s orbit, reach lunar destinations, and explore deep space. The new contract awards include:Subcategory 1.2: DTE Geostationary (“GEO”) to Cislunar DTE Services, offering enhanced data transmission capabilities and autonomous operations. Subcategory 1.3: xCislunar DTE Services, addressing mission needs for highly elliptical...

DALLAS, Dec. 23, 2024 (GLOBE NEWSWIRE) — Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, is pleased to announce that on December 20, 2024 the Company received a “moot” letter from Nasdaq confirming that the Company has regained compliance with all applicable listing standards for its continued listing on the Nasdaq Capital Market and that a further hearing regarding the Company’s compliance is no longer necessary. “I am thrilled to announce that we continue to successfully meet our Nasdaq’s compliance standards,” said Dr. Michael DiMaio, Chairman of Spectral AI’s Board of Directors. “This confirmation reflects our team’s...

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) targets the same peptide and has the same CD3 effector and TCR specificity as brenetafusp, and is designed with extended half-life   The Phase 1 trial will assess the safety and clinical activity of IMC-P115C in HLA-A*02:01-positive patients with advanced solid tumors that express PRAME (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 23 December 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases,...